Last updated: September 3, 2026
Iloprost is a mature pulmonary arterial hypertension (PAH) therapy with declining strategic importance in the United States and Europe. Its principal branded product, Ventavis, competes with longer-acting inhaled and oral prostacyclin-pathway drugs, including treprostinil, selexipag and oral prostacyclin analogues. Regulatory exclusivity has expired, product-level revenue is no longer separately reported by major pharmaceutical companies, and commercial value is concentrated in generic supply, hospital use and selected international markets.
What is iloprost and which products contain it?
Iloprost is a synthetic prostacyclin analogue that produces pulmonary and systemic vasodilation and inhibits platelet aggregation. Its principal approved use in the United States is the treatment of pulmonary arterial hypertension in patients with WHO functional class III symptoms.
| Product |
Active ingredient |
Administration |
Principal market |
Originator or major marketer |
| Ventavis |
Iloprost |
Inhalation solution through a nebulizer |
United States and selected international markets |
Actelion, later associated with Johnson & Johnson |
| Ilomedin |
Iloprost |
Intravenous infusion |
Europe and other international markets |
Bayer |
| Generic iloprost |
Iloprost |
Mainly inhaled or parenteral formulations, depending on jurisdiction |
International and selected regulated markets |
Multiple regional manufacturers |
The U.S. Food and Drug Administration approved Ventavis on December 29, 2004, under NDA 021779 for PAH.[1] Ilomedin has been marketed outside the United States for hospital-based treatment of severe peripheral vascular disease and other vascular indications, subject to national approvals.[2]
How large is the iloprost market?
The global iloprost market is a mature niche within the wider PAH and prostacyclin market. Public companies generally do not disclose standalone iloprost revenue, so market size must be assessed through product positioning, reported segment data and prescription trends rather than audited product sales.
The commercial market has four characteristics:
- PAH remains a specialized, high-value disease area, but treatment has shifted toward combination regimens.
- Iloprost has a short duration of action and requires repeated inhalations during the day.
- Newer products provide longer exposure, oral administration or more convenient inhaled delivery.
- Generic competition and loss of regulatory exclusivity have reduced branded pricing power.
Iloprost retains value in patients who require inhaled prostacyclin therapy but cannot tolerate or access alternative products. Its use is more defensible in markets where parenteral or newer inhaled therapies are unavailable, restricted by price, or limited by reimbursement rules.
What is the financial trajectory for iloprost?
Iloprost revenue has likely followed a long-term decline from branded peak sales, although exact product-level figures are not publicly reported.
Historical revenue drivers
Ventavis benefited from:
- Orphan-drug positioning in PAH.
- Limited early competition in inhaled prostacyclin therapy.
- High treatment costs associated with specialty pulmonary hypertension care.
- Specialist prescribing by pulmonary hypertension centers.
Its commercial position weakened after the introduction and broader adoption of:
- Inhaled treprostinil, including Tyvaso.
- Oral selexipag, marketed as Uptravi.
- Endothelin-receptor antagonists such as bosentan, ambrisentan and macitentan.
- PDE-5 inhibitors such as sildenafil and tadalafil.
- Combination treatment protocols that reduce reliance on short-acting inhaled iloprost.
Johnson & Johnson reports its pharmaceutical performance through broad therapeutic and geographic categories. It does not separately report Ventavis revenue in current annual filings.[3] Bayer also reports products through business-unit and portfolio-level disclosures rather than separate Ilomedin revenue.[4]
Financial trajectory by period
| Period |
Commercial position |
Revenue direction |
| 2004-2009 |
U.S. launch and early specialty adoption |
Growth from a small PAH base |
| 2010-2015 |
Established inhaled prostacyclin; increasing competition |
Stable to declining |
| 2016-2020 |
Stronger competition from Tyvaso and Uptravi; generic pressure in some markets |
Declining |
| 2021-2024 |
Mature product with limited differentiation |
Low-growth or declining branded revenue |
| 2025 onward |
Primarily a niche and generic opportunity |
Stable only in selected markets |
The largest economic pressure is not disease-market contraction. PAH remains a high-cost specialty market. The pressure is product substitution. Treprostinil products offer longer dosing intervals or broader delivery options, while oral agents are easier for many patients to use. Iloprost therefore captures a smaller share of a growing or stable PAH market.
When did iloprost lose regulatory exclusivity?
Ventavis received U.S. approval in 2004. Its principal U.S. regulatory exclusivities have expired.
| Exclusivity |
Approximate end point |
Status |
| New chemical entity exclusivity |
December 2009 |
Expired |
| Orphan-drug exclusivity, if applied to the approved indication |
December 2011 |
Expired |
| Patent-based exclusivity |
Earlier listed rights have expired or ceased to provide meaningful branded protection |
No current strategic barrier comparable to launch-era protection |
The U.S. approval created a seven-year orphan-drug period for the approved indication if the product was designated and approved under the orphan-drug framework. That period did not prevent development of products for different indications or different active ingredients.
There is no remaining regulatory exclusivity that supports premium pricing for the original U.S. product. Current commercial protection depends on manufacturing capability, device compatibility, physician familiarity, reimbursement and local registration status.
What patents protect iloprost products?
Iloprost patent protection historically covered the active compound, stereochemical forms, pharmaceutical compositions, inhalation delivery and therapeutic use. The important commercial point is that the foundational protection is old.
Patent estate status
The original iloprost molecule was discovered decades before Ventavis reached the U.S. market. Any original composition-of-matter rights have expired in the major pharmaceutical jurisdictions. Later patents covered:
- Iloprost formulations.
- Nebulized administration.
- Dose and inhalation schedules.
- Use in PAH and vascular disorders.
- Device-specific delivery systems.
- Manufacturing and purification processes.
Those later rights generally had expiration dates tied to filings in the 1990s and early 2000s. Patent term extensions and supplementary protection certificates may have prolonged protection in selected jurisdictions, but they do not create a globally coordinated exclusivity period.
The current estate is therefore fragmented. Formulation and device patents can still affect a particular generic or delivery system, but they are less likely to block all iloprost competition.
How strong is the iloprost patent estate?
The estate is weak as a broad market barrier and moderate for specific delivery configurations.
| Patent category |
Current commercial strength |
| Original iloprost compound |
Low; foundational rights expired |
| PAH method-of-use claims |
Low to moderate; many claims are old and indication-specific |
| Inhalation formulation |
Moderate for narrowly claimed compositions |
| Nebulizer or device configuration |
Moderate where a product depends on a protected device |
| Manufacturing process |
Moderate if process complexity affects quality or cost |
| Broad market exclusivity |
Low |
The main remaining barrier is technical execution. Iloprost is a potent compound used at low doses, and inhaled products require consistent concentration, sterility where applicable, device compatibility and reproducible aerosol performance. A competitor may avoid a blocking formulation claim while still facing regulatory and manufacturing challenges.
Are there Paragraph IV challenges to Ventavis?
Paragraph IV risk is limited because Ventavis no longer has the regulatory or patent profile of a newly protected specialty product. A generic applicant can challenge listed patents by asserting that a patent is invalid, unenforceable or not infringed.
For Ventavis, the principal risk period for Paragraph IV litigation was during the years when relevant U.S. patents remained listed in the Orange Book. Current commercial risk is more likely to arise through:
- An ANDA based on a non-infringing formulation.
- A 505(b)(2) application for a modified inhaled product.
- A product using a different nebulizer or delivery platform.
- International generic registrations outside the U.S. patent system.
No major, current Paragraph IV dispute has materially changed the commercial outlook for iloprost based on publicly available FDA and company disclosures.[5]
What is the Orange Book status of Ventavis?
Ventavis is an older approved inhalation product. Its Orange Book relevance is primarily regulatory rather than exclusivity-driven.
The key issues for a generic applicant are:
- Whether the reference product remains commercially available in sufficient quantities.
- Whether the proposed product must use the same or a therapeutically equivalent delivery system.
- Whether the formulation can demonstrate pharmaceutical equivalence.
- Whether the FDA requires comparative performance data for the nebulizer.
- Whether device differences affect substitutability.
An inhaled generic can face a more complex approval pathway than a conventional oral tablet. The active ingredient alone does not determine equivalence. Aerosol particle size, emitted dose, nebulization time and delivery efficiency can affect clinical performance.
What generic entry risks exist for iloprost?
Generic entry risk is high for the active ingredient and moderate for the finished inhaled product.
U.S. generic risks
The main U.S. risk factors are:
- Expired regulatory exclusivity.
- Old or absent patent barriers.
- A relatively small but medically defined patient population.
- Device and formulation requirements.
- Limited commercial scale compared with oral PAH drugs.
- Potential difficulty securing payer coverage against established therapies.
A generic manufacturer may not need to displace all Ventavis use. It can target hospitals, specialty pharmacies or payers seeking lower-cost alternatives. Price erosion is likely to be significant if multiple suppliers enter, but the small market may limit the number of economically attractive entrants.
International generic risks
International competition is stronger because iloprost has been used for more indications and in more dosage forms. European and Asian markets may include intravenous or inhaled products supplied by regional manufacturers. Pricing varies substantially by country because hospital procurement, reference pricing and reimbursement policies differ.
The greatest geographic opportunity is in markets where:
- Iloprost is included in public hospital formularies.
- Generic registration is less dependent on U.S.-style device equivalence.
- Intravenous prostacyclin therapy remains common.
- Newer PAH therapies carry high reimbursement restrictions.
How does iloprost compare with competing PAH drugs?
| Drug |
Route |
Dosing convenience |
Competitive position |
| Iloprost |
Inhaled; intravenous in some markets |
Frequent inhalations or hospital infusion |
Mature, niche therapy |
| Treprostinil |
Inhaled, oral, subcutaneous or intravenous |
More flexible depending on product |
Stronger commercial position |
| Epoprostenol |
Intravenous |
Continuous infusion |
Used in severe disease; high administration burden |
| Selexipag |
Oral |
Twice daily |
Strong alternative for prostacyclin-pathway treatment |
| Sildenafil/tadalafil |
Oral |
Once or multiple times daily |
Broad use, lower administration burden |
| Macitentan and other ERAs |
Oral |
Usually once daily |
Common foundation or combination therapy |
Iloprost’s strongest advantage is established physician experience and a familiar inhaled prostacyclin mechanism. Its principal disadvantages are frequent dosing, device dependence and limited differentiation from newer prostacyclin-pathway products.
What licensing deals and ownership changes affect iloprost?
The most relevant ownership event was Johnson & Johnson’s acquisition of Actelion in 2017. Actelion’s PAH portfolio included Ventavis, while Johnson & Johnson also obtained major commercial rights and development assets in pulmonary hypertension.[6]
Bayer remains associated with Ilomedin in markets where the product is marketed through Bayer’s pharmaceutical operations.[4] Product rights differ by country, and the company holding the U.S. NDA may not control every international iloprost presentation.
There has been no recent transaction that materially repositions iloprost as a growth product. Deal value in PAH has shifted toward longer-acting therapies, oral agents, combination regimens and novel pulmonary vascular biology.
What litigation affects iloprost?
Iloprost is not currently associated with a major global patent litigation campaign comparable to disputes surrounding newer high-revenue medicines. Any remaining disputes are more likely to concern:
- Local formulation rights.
- Device compatibility.
- Trademark or regulatory approval issues.
- Generic substitution.
- Hospital procurement and reimbursement.
The absence of major litigation is commercially important. It indicates that legal exclusivity is no longer the primary determinant of iloprost performance. Price, supply reliability and regulatory execution now have greater influence.
What is the future market outlook for iloprost?
The base case is a declining branded market with durable demand in specialist and international settings.
Downside factors
- Continued conversion to oral PAH therapy.
- Expansion of inhaled treprostinil.
- Generic price erosion.
- Low patient convenience.
- Limited promotional investment by the originator.
- Greater use of early combination therapy that reduces reliance on rescue or add-on inhaled iloprost.
Stabilizing factors
- Persistent need for prostacyclin-pathway therapy.
- Clinical familiarity in specialist centers.
- Use in patients who cannot tolerate oral therapies.
- Hospital demand for intravenous iloprost in some countries.
- Regulatory barriers to fully substitutable inhaled products.
- Availability gaps for newer PAH drugs in lower-income markets.
The most credible commercial scenario is a low-growth, low-margin mature product category. A manufacturer can still create value through low-cost production, reliable supply, regional registrations or a differentiated nebulizer. A return to blockbuster economics is unlikely without a new delivery technology or a new approved indication.
Key Takeaways
- Iloprost is a mature prostacyclin analogue used mainly in PAH and selected vascular indications.
- Ventavis received FDA approval in 2004; its U.S. regulatory exclusivity has expired.
- Product-level revenue is not separately disclosed by Johnson & Johnson or Bayer.
- Branded iloprost revenue has likely declined as treprostinil, selexipag and oral PAH therapies expanded.
- The foundational patent estate is expired; remaining protection is narrow and formulation- or device-specific.
- Generic entry risk is high for the active ingredient and moderate for inhaled finished products.
- No major current Paragraph IV or global patent litigation campaign is driving the market.
- Commercial value remains in generic supply, hospital channels and countries where newer PAH therapies are less accessible.
- The likely financial trajectory is continued branded decline, with stable niche demand rather than renewed growth.
Frequently Asked Questions
Is iloprost still commercially available?
Yes. Availability depends on the country, dosage form and marketing authorization holder. Ventavis is the principal U.S. inhaled reference product, while Ilomedin and regional generic products are used in international markets.
Is iloprost a biologic or a small-molecule drug?
Iloprost is a small-molecule prostacyclin analogue. Biosimilar regulation does not apply. Competition occurs through generic, hybrid or locally approved pharmaceutical products.
Can iloprost be used for peripheral arterial disease?
Iloprost has been used and approved in some jurisdictions for severe peripheral vascular disease, critical limb ischemia and thromboangiitis obliterans. The approved indications differ by country and formulation.
Why has iloprost lost share despite growth in PAH treatment?
The PAH market has shifted toward oral drugs, longer-acting prostacyclin therapies and combination regimens. Iloprost requires repeated inhalations, which limits convenience and adherence compared with several competing products.
Does iloprost have meaningful manufacturing barriers?
Yes, but they are technical rather than broad patent barriers. Consistent low-dose manufacturing, formulation stability, aerosol performance, nebulizer compatibility and regulatory equivalence can make entry more difficult than for a standard oral generic.
References
- U.S. Food and Drug Administration. (2004). Ventavis (iloprost) inhalation solution: New drug application 021779 and prescribing information.
- European Medicines Agency. (n.d.). Iloprost-containing medicinal products and European product information.
- Johnson & Johnson. (2024). Annual report for the fiscal year ended December 31, 2023.
- Bayer AG. (2024). Annual report 2023.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Johnson & Johnson. (2017). Johnson & Johnson completes acquisition of Actelion.
